Effectiveness of Mindfulness Based Cognitive Therapy in adults with high-functioning autism

Effectiveness of Mindfulness Based Cognitive Therapy in adults with high-functioning autism - mindfulness and autism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON32624

Enrollment

Registered

2010-10-28

Start date

2010-01-04

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autism autism spectrum disorder

Interventions

individual weekly MBCT sessions (2 hrs). Client has to excercise at least 6 days/wk

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Treatment groups meet DSM-IV/TR and ADI-R criteria for autistic disorder or Asperger disorder. Age 18-60. WAIS-III IQ score >85. Suffer from depressive complaints and/or sensory over-excitability Control group: matched on gender and age.

Exclusion criteria

Exclusion criteria: Treatment group: no comorbid neuropsychiatric disorders such as substance abuse, epilepsy, neuropathologies Control group: no known neuropsychiatric disorders such as depression, addiction, epilepsy, neuropathology; use of psycho-active medication.

Design outcomes

Primary

Measure	Time frame
Depressive complaints: SCL-90 scores Sensory processing:AASP scores mindfulness skills: FFMQ scores interpersonal functioning and functioning in society : OQ-45 scores neurometric measures: * quantitative EEG (qEEG); spectral parameters; coherence measures * Event Related Potentials measures: latency/amplitude N2/P3 components * neuropsychological measures (reaction times, error rates etc.) * autonomous nervous system measures (heart rate variability, electrodermal activity)	—

Measure

Time frame

Depressive complaints: SCL-90 scores Sensory processing:AASP scores mindfulness skills: FFMQ scores interpersonal functioning and functioning in society : OQ-45 scores neurometric measures: * quantitative EEG (qEEG); spectral parameters; coherence measures * Event Related Potentials measures: latency/amplitude N2/P3 components * neuropsychological measures (reaction times, error rates etc.) * autonomous nervous system measures (heart rate variability, electrodermal activity)

—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)